Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20306004 | 0.83 | ALDH1A1 (0.49) | GAAALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL29942878 | 0.81 | KDM4E (0.54) | GAAALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL14956928 | 0.81 | ALDH1A1 (0.47) | GAAALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL1266209 | 0.81 | KDM4E (0.54) | GAAALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL23797063 | 0.80 | NNMT (0.53) | GAAALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL510468 | 0.80 | ABL1 (0.53) | GAAALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL11179056 | 0.80 | KDM4E (0.46) | GAAALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL18555299 | 0.80 | KDM4E (0.46) | GAAALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL4737223 | 0.79 | SMN1; SMN2 (0.55) | GAAALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL10464949 | 0.79 | NPSR1 (0.50) | GAAALDH1A1KDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019383-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2025-01-16 | — | — | US | disclosed |
| CN-119039288-A | Pyrido [2,3-d ] pyrimidine derivatives as inhibitors of HIV replication | VIIV保健英国第五有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-12129255-B2 | Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2024-10-29 | — | — | US | disclosed |
| CN-114245795-B | Pyrido [2,3-d ] pyrimidine derivatives as inhibitors of HIV replication | VIIV保健英国第五有限公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-3986561-B1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2024-02-14 | — | — | EP | disclosed |
| US-20230149408-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20230149408-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20230106880-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| EP-3917930-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-03-01 | — | — | EP | disclosed |
| EP-4135702-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021209900-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021209900-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-10-21 | — | — | WO | disclosed |
| US-20210323967-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-10-21 | — | — | US | disclosed |
| US-20210323967-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-10-21 | — | — | US | disclosed |
| WO-2021176367-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021176367-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-09-10 | — | — | WO | disclosed |
| WO-2020254985-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254985-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020157692-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157692-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149408-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | POLR2H, POLR2E, EIF2AK2 | GAA 651/4885ALDH1A1 3719/4885KDM4E 1960/4885 |
| US-20250019383-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DPYD | GAA 2209/4885ALDH1A1 3477/4885KDM4E 1598/4885 |
| US-20210323967-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DPYD | GAA 2209/4885ALDH1A1 3477/4885KDM4E 1598/4885 |
| US-12129255-B2 | Pyrido [2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication | TYMP, TYMS, DPYD | GAA 2209/4885ALDH1A1 3477/4885KDM4E 1598/4885 |
| US-20230106880-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | GAA 327/4885ALDH1A1 3324/4885KDM4E 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.